1 week Ago By Defense World Staff
Invesco Ltd. grew its stake in Arcus Biosciences, Inc. (NYSE:RCUS – Free Report) by 21.
4% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 203,987 shares of the company’s stock after buying an additional 35,905 shares during the period. Invesco Ltd.
owned 0.22% of Arcus Biosciences worth $3,037,000 at the end of the most recent reporting period. A number of other hedge funds have also recently modified their holdings of the stock.
R Squared Ltd acquired a new position in Arcus Biosciences in the fourth quarter valued at $26,000. US Bancorp DE boosted its position in shares of Arcus Biosciences by 2,432.0% in the 4th quarter.
US Bancorp DE now owns 6,887 shares of the company’s stock valued at $103,000 after purchasing an additional 6,615 shares during the period. AXQ Capital LP purchased a new position in Arcus Biosciences during the 4th quarter worth approximately $160,000. KLP Kapitalforvaltning AS acquired a new position in Arcus Biosciences during the fourth quarter worth approximately $207,000.
Finally, Teacher Retirement System of Texas lifted its stake in Arcus Biosciences by 19.2% in the fourth quarter. Teacher Retirement System of Texas now owns 14,952 shares of the company’s stock valued at $223,000 after buying an additional 2,410 shares during the last quarter.
92.89% of the stock is owned by hedge funds and other institutional investors. Arcus Biosciences Stock PerformanceNYSE RCUS opened at $8.
30 on Monday. The company has a current ratio of 5.24, a quick ratio of 5.
24 and a debt-to-equity ratio of 0.08. The business’s 50 day moving average is $8.
79 and its two-hundred day moving average is $13.01. The stock has a market capitalization of $872.
65 million, a price-to-earnings ratio of -2.63 and a beta of 1.54.
Arcus Biosciences, Inc. has a 12-month low of $6.50 and a 12-month high of $18.
98. Arcus Biosciences (NYSE:RCUS – Get Free Report) last released its quarterly earnings data on Tuesday, February 25th. The company reported ($1.
03) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.17) by $0.14.
The firm had revenue of $36.00 million during the quarter, compared to analysts’ expectations of $29.38 million.
Arcus Biosciences had a negative return on equity of 45.59% and a negative net margin of 102.66%.
Research analysts expect that Arcus Biosciences, Inc. will post -3.15 EPS for the current year.
Wall Street Analyst Weigh InA number of equities analysts have recently issued reports on the stock. Barclays cut their target price on shares of Arcus Biosciences from $29.00 to $14.
00 and set an “overweight” rating on the stock in a report on Wednesday, April 23rd. Bank of America dropped their price objective on shares of Arcus Biosciences from $22.00 to $17.
00 and set a “neutral” rating on the stock in a research note on Wednesday, February 19th. HC Wainwright upgraded shares of Arcus Biosciences from a “neutral” rating to a “buy” rating and increased their target price for the stock from $18.00 to $24.
00 in a research note on Wednesday, February 26th. Finally, Morgan Stanley dropped their price target on Arcus Biosciences from $36.00 to $25.
00 and set an “overweight” rating on the stock in a research report on Tuesday, February 18th. One investment analyst has rated the stock with a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the stock presently has an average rating of “Buy” and a consensus price target of $28.
38.Check Out Our Latest Report on Arcus BiosciencesInsider ActivityIn other news, Director Yasunori Kaneko purchased 20,000 shares of the stock in a transaction that occurred on Thursday, February 27th. The shares were acquired at an average price of $10.
06 per share, for a total transaction of $201,200.00. Following the acquisition, the director now directly owns 28,400 shares in the company, valued at approximately $285,704.
The trade was a 238.10 % increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.
Also, CEO Terry J. Rosen acquired 19,800 shares of the company’s stock in a transaction that occurred on Thursday, February 27th. The stock was purchased at an average cost of $10.
18 per share, with a total value of $201,564.00. Following the completion of the purchase, the chief executive officer now directly owns 2,554,160 shares in the company, valued at $26,001,348.
80. This represents a 0.78 % increase in their ownership of the stock.
The disclosure for this purchase can be found here. Insiders own 12.30% of the company’s stock.
Arcus Biosciences Profile (Free Report)Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies.Featured StoriesFive stocks we like better than Arcus BiosciencesWhat is a SEC Filing?Texas Instruments: Earnings Beat, Upbeat Guidance Fuel RecoveryWhat Are Dividend Achievers? An IntroductionO’Reilly Automotive: An Anytime Buy for Buy-and-Hold InvestorsValue Investing: Is it a Good Strategy in 2022? (Hint: Always)Chipotle Mexican Grill Serves Smoking Hot Entry Point in Q2Want to see what other hedge funds are holding RCUS? Visit HoldingsChannel.
com to get the latest 13F filings and insider trades for Arcus Biosciences, Inc. (NYSE:RCUS – Free Report)..
